$2.58
Today
as of Jul 22, 16:48 ET
Last 30 days
Recent Press Releases & News
FATE Stock Jumps 6% As FDA Greenlights Moving Cell Therapy To Clinical Trials
Update: Fate Therapeutics Shares Rise After FDA Clears Investigational New Drug Application for FT839
Fate Therapeutics Receives FDA Clearance of Investigational New Drug Application for FT839 Product Candidate
Overview
52-week range
$0.91
$2.88
85% of range
Avg surprise (last 3)
+15.1%
Avg reaction (last 2)
-5.7%
0% positive
Latest IV / EM
123%
EM ±28.1% · $3 · Aug 21
Earnings trends
EPS — actual vs estimate
Actual Estimate
Revenue vs Net Income
Revenue Net income
Earnings history
| Date | Period | Actual EPS | Est | Surprise | YoY %Δ | Day react | Source |
|---|---|---|---|---|---|---|---|
| Wed May 13, 2026 | Mar/2026 | $-0.26 | $-0.29 | +10.3% | +18.8% | -4.9% | earnings |
| Tue Sep 30, 2025 | Sep 2025 | $-0.27 | — | — | — | — | financials |
| Tue Aug 12, 2025 | Jun/2025 | $-0.29 | $-0.35 | +17.1% | — | — | earnings |
| Tue May 13, 2025 | Mar/2025 | $-0.32 | $-0.39 | +17.9% | — | -6.5% | earnings |
| Mon Sep 30, 2024 | Sep 2024 | $-0.40 | — | — | — | — | financials |
| Sun Jun 30, 2024 | Jun 2024 | $-0.33 | — | — | — | — | financials |
| Sun Mar 31, 2024 | Mar 2024 | $-0.47 | — | — | — | — | financials |
| Sat Sep 30, 2023 | Sep 2023 | $-0.46 | — | — | — | — | financials |
| Fri Jun 30, 2023 | Jun 2023 | $-0.54 | — | — | — | — | financials |
Upcoming
| Date | Fiscal | Time | EPS Est | LY EPS | YoY %Δ |
|---|---|---|---|---|---|
| Tue Aug 11, 2026 | Jun/2026 | OTHER | -$0.28 | -$0.29 | +3.5% |
Financials
Income statement (quarterly)
| Metric | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $1M | — | $2M | $2M | $2M | — | $3M | $7M |
| Cost of revenue | — | — | — | — | — | — | — | — |
| Gross profit | — | — | — | — | — | — | — | — |
| Operating income | $-33M | — | $-35M | $-37M | $-41M | — | $-52M | $-45M |
| Net income | $-31M | — | $-32M | $-34M | $-38M | — | $-48M | $-38M |
| EPS (diluted) | $-0.26 | — | $-0.27 | $-0.29 | $-0.32 | — | $-0.40 | $-0.33 |
Balance sheet (quarterly)
| Metric | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 |
|---|---|---|---|---|---|---|---|---|
| Cash & equivalents | $40M | $47M | $41M | $41M | $45M | $36M | $38M | $37M |
| Inventory | — | — | — | — | — | — | — | — |
| Total current assets | $180M | $209M | $221M | $230M | $248M | $292M | $310M | $319M |
| Total assets | $285M | $319M | $344M | $372M | $399M | $441M | $495M | $529M |
| Long-term debt | — | — | — | — | — | — | — | — |
| Total liabilities | — | — | — | — | — | — | — | — |
| Total equity | $180M | $207M | $234M | $261M | $288M | $319M | $362M | $397M |